GLS and acute lymphoblastic leukemia: Therefore, reducing the glutaminase co-activity of available L-ASNase may be advantageous to lessen toxic side effects, enabling patients to complete their treatments and, improve their outcomes as well as be used more frequently in the treatment of adults with ALL.